Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology
Mesenchymal chondrosarcoma is a rare but deadly form of chondrosarcoma that typically affects adolescents and young adults. While curative intent is possible for patients with localized disease, few options exist for patients in the unresectable/metastatic setting. Thus, it is imperative to understand the fusion-driven biology of this rare malignant neoplasm so as to lead to the future development of better therapeutics for this disease. This manuscript will briefly review the clinical and pathologic features of mesenchymal chondrosarcoma followed by an appraisal of existing data linked to the fusions, HEY1-NCOA2 and IRF2BP2-CDX1, and the associated downstream pathways.
KeywordsMesenchymal chondrosarcoma Chondrosarcoma Fusion Translocation Notch HEY1 NCOA2 IRF2BP2 CDX1 Chromatin remodeling TGF beta Apoptosis Genomics Pathways
Compliance with Ethical Standards
Conflict of Interest
Marc El Beaino declares that he has no conflict of interest.
Jason Roszik declares that he has no conflict of interest.
John A. Livingston declares that he has no conflict of interest.
Wei-Lien Wang declares that he has no conflict of interest.
Alexander J. Lazar declares that he has no conflict of interest.
Behrang Amini declares that he has no conflict of interest.
Vivek Subbiah has received research support through grants from Novartis, Bayer, AbbVie, and Roche/Genentech.
Valerae Lewis declares that she has no conflict of interest.
Anthony P. Conley declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Lichtenstein L, Bernstein D. Unusual benign and malignant chondroid tumors of bone. A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer. 1959;12(6):1142–57. https://doi.org/10.1002/1097-0142(195911/12)12:6<1142::AID-CNCR2820120610>3.0.CO;2-D.CrossRefGoogle Scholar
- 2.Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study. Eur J Cancer. 2015;51(3):374–81. https://doi.org/10.1016/j.ejca.2014.11.007.CrossRefPubMedGoogle Scholar
- 3.• Schneiderman BA, Kliethermes SA, Nystrom LM. Survival in mesenchymal chondrosarcoma varies based on age and tumor location: a survival analysis of the SEER database. Clin Orthop Relat Res. 2017;475(3):799–805. This is a study that evaluates prognosticators of mesenchymal chondrosarcoma in 205 patients identified via the SEER database. It showed that the main poor prognostic factors were tumor size and presence of metastases at diagnosis. Young patients and/or cranial disease had better survival when compared to older patients and/or axial or appendicular tumors CrossRefPubMedGoogle Scholar
- 8.Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008;112(11):2424–31. https://doi.org/10.1002/cncr.23457.CrossRefPubMedGoogle Scholar
- 11.• Xu J, et al. Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years. PLoS One. 2015;10(4):e0122216. The authors of this study searched medical libraries for all mesenchymal chondrosarcoma cohort reports available in the literature. They showed that surgery constitutes the mainstay therapy for localized disease. Survival was not affected with adjuvant radiation or chemotherapy. CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012;51(2):127–39. https://doi.org/10.1002/gcc.20937.CrossRefPubMedGoogle Scholar
- 13.Nakayama R, Miura Y, Ogino J, Susa M, Watanabe I, Horiuchi K, et al. Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma. Pathol Int. 2012;62(12):823–6. https://doi.org/10.1111/pin.12022.CrossRefPubMedGoogle Scholar
- 14.Heisig J, Weber D, Englberger E, Winkler A, Kneitz S, Sung WK, et al. Target gene analysis by microarrays and chromatin immunoprecipitation identifies HEY proteins as highly redundant bHLH repressors. PLoS Genet. 2012;8(5):e1002728. https://doi.org/10.1371/journal.pgen.1002728.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Taelman V, van Wayenbergh R, Sölter M, Pichon B, Pieler T, Christophe D, et al. Sequences downstream of the bHLH domain of the Xenopus hairy-related transcription factor-1 act as an extended dimerization domain that contributes to the selection of the partners. Dev Biol. 2004;276(1):47–63. https://doi.org/10.1016/j.ydbio.2004.08.019.CrossRefPubMedGoogle Scholar
- 23.Kathiriya IS, King IN, Murakami M, Nakagawa M, Astle JM, Gardner KA, et al. Hairy-related transcription factors inhibit GATA-dependent cardiac gene expression through a signal-responsive mechanism. J Biol Chem. 2004;279(52):54937–43. https://doi.org/10.1074/jbc.M409879200.CrossRefPubMedGoogle Scholar
- 24.Fischer A, Klattig J, Kneitz B, Diez H, Maier M, Holtmann B, et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol. 2005;25(20):8960–70. https://doi.org/10.1128/MCB.25.20.8960-8970.2005.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.de Jong DS, Steegenga WT, Hendriks JMA, van Zoelen EJJ, Olijve W, Dechering KJ. Regulation of Notch signaling genes during BMP2-induced differentiation of osteoblast precursor cells. Biochem Biophys Res Commun. 2004;320(1):100–7. https://doi.org/10.1016/j.bbrc.2004.05.150.CrossRefPubMedGoogle Scholar
- 31.Zamurovic N, Cappellen D, Rohner D, Susa M. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem. 2004;279(36):37704–15. https://doi.org/10.1074/jbc.M403813200.CrossRefPubMedGoogle Scholar
- 33.Sharff KA, Song WX, Luo X, Tang N, Luo J, Chen J, et al. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem. 2009;284(1):649–59. https://doi.org/10.1074/jbc.M806389200.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.•• Tsuru A, et al. Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression. Br J Cancer. 2015;112(7):1232–40. This basic science report aimed to detect the relationship between HEY1 and osteosarcoma. The authors used human cell lines and a murine xenograft model for this purpose. They found that HEY1 promotes osteosarcoma’s metastatic potential by upregulating matrix metalloproteinase 9 expression. CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Strehl S, Nebral K, Konig M, Harbott J, Strobl H, Ratei R, et al. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clin Cancer Res. 2008;14(4):977–83. https://doi.org/10.1158/1078-0432.CCR-07-4022.CrossRefPubMedGoogle Scholar
- 44.Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, et al. A molecular study of pediatric spindle and Sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40(2):224–35. https://doi.org/10.1097/PAS.0000000000000538.PubMedPubMedCentralGoogle Scholar
- 45.Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49(3):224–36. https://doi.org/10.1002/gcc.20731.PubMedPubMedCentralGoogle Scholar
- 46.Meloni-Ehrig A, Smith B, Zgoda JA, Greenberg J, Perdahl-Wallace E, Zaman S, et al. Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;191(1):43–5. https://doi.org/10.1016/j.cancergencyto.2009.01.010.CrossRefPubMedGoogle Scholar
- 47.Hosoi H, Kakazu N, Konishi E, Tsuchihashi Y, Hada S, Amaya E, et al. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;189(2):98–104. https://doi.org/10.1016/j.cancergencyto.2008.10.016.CrossRefPubMedGoogle Scholar
- 48.Jin Y, Möller E, Nord KH, Mandahl N, von Steyern FV, Domanski HA, et al. Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer. 2012;51(5):510–20. https://doi.org/10.1002/gcc.21939.CrossRefPubMedGoogle Scholar
- 49.Panagopoulos I, Gorunova L, Viset T, Heim S. Gene fusions AHRR-NCOA2, NCOA2-ETV4, ETV4-AHRR, P4HA2-TBCK, and TBCK-P4HA2 resulting from the translocations t(5;8;17)(p15;q13;q21) and t(4;5)(q24;q31) in a soft tissue angiofibroma. Oncol Rep. 2016;36(5):2455–62. https://doi.org/10.3892/or.2016.5096.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.•• Yu J, et al. Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer. Oncogene. 2016;35(2):187–95. The authors identified a LACTB2-NCOA2 fusion in colorectal cancer cases with low NCOA2 expression. Inhibiting and expressing NCOA2 in normal colonocytes and colorectal cancer cells induced and repressed their tumorigenic properties, respectively. LACTB2-NCOA2 is a recurrent fusion responsible of disrupting wild-type NCOA2 in colorectal cancer. CrossRefPubMedGoogle Scholar
- 60.Nyquist KB, Panagopoulos I, Thorsen J, Haugom L, Gorunova L, Bjerkehagen B, et al. Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS One. 2012;7(11):e49705. https://doi.org/10.1371/journal.pone.0049705.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999;181(3):393–409. https://doi.org/10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6.CrossRefPubMedGoogle Scholar
- 73.van Oosterwijk JG, Meijer D, van Ruler MAJH, van den Akker BEWM, Oosting J, Krenács T, et al. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets. Am J Pathol. 2013;182(4):1347–56. https://doi.org/10.1016/j.ajpath.2012.12.036.CrossRefPubMedGoogle Scholar
- 79.•• de Jong Y, et al. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Lab Invest. 2016;96(10):1128–37. This study reports on a derived mesenchymal chondrosarcoma cell line, MCS170, in which the HEY1-NCOA2 translocation was identified. The authors investigated its response to doxorubicin, cisplatin and/or Bcl-2 family members inhibitors. Apoptosis induction and MCS170 sensitization to chemotherapy were achieved when combining Bcl-2 family members inhibitors with conventional chemotherapy. CrossRefPubMedGoogle Scholar
- 81.Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668–81. https://doi.org/10.1016/j.ccell.2014.10.004.CrossRefPubMedPubMedCentralGoogle Scholar